TY - JOUR
T1 - Is there an association between prenatal testosterone and autistic traits in adolescents?
AU - Dooley, Niamh
AU - Ruigrok, Amber
AU - Holt, Rosemary
AU - Allison, Carrie
AU - Tsompanidis, Alexandros
AU - Waldman, Jack
AU - Auyeung, Bonnie
AU - Lombardo, Michael V.
AU - Baron-Cohen, Simon
N1 - Funding Information:
We thank the participants and their parents who have devoted their time to Fetal Testosterone study. We also thank Varun Warrier for his helpful comments on this manuscript. The study was supported by the Wellcome Trust ( RG69312 , RG58828 , RNAG/528 ), the Autism Research Trust , the Templeton World Charitable Foundation and the National Institute for Health Research (UK) Biomedical Research Center Cambridge . ND was funded by a StAR (Strategic Academic Recruitment) PhD scholarship ( 2340D ) and an International Secondment Award ( 19180A04 ) from the Royal College of Surgeons in Ireland . AR, RH and SBC were funded by EU-AIMS (European Autism Interventions - A Multicentre Study for Developing New Medications; 115300: FP7/2007-2013 ), the Templeton World Charitable Foundation, the Simons Foundation Autism Research Initiative ( SFARI ) , the Autism Research Trust and the Innovative Medicines Initiative 2 Joint Undertaking ( JU; 777394 ). The JU receives support from the European Union’s Horizon 2020 Research and Innovation Program and EFPIA and AUTISM SPEAKS , Autistica, SFARI. MVL was supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program ( 755816 ). BA was funded by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement ( 813546 ), the Baily Thomas Charitable Fund ( TRUST/VC/AC/SG/469207686 ), the Data Driven Innovation Program and the UK Economic and Social Research Council ( ES/N018877/1 ). SBC was funded by the National Institute of Health Research (NIHR) Applied Research Collaboration East of England (ARC EoE) program. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the funders.
Funding Information:
We thank the participants and their parents who have devoted their time to Fetal Testosterone study. We also thank Varun Warrier for his helpful comments on this manuscript. The study was supported by the Wellcome Trust (RG69312, RG58828, RNAG/528), the Autism Research Trust, the Templeton World Charitable Foundation and the National Institute for Health Research (UK) Biomedical Research Center Cambridge. ND was funded by a StAR (Strategic Academic Recruitment) PhD scholarship (2340D) and an International Secondment Award (19180A04) from the Royal College of Surgeons in Ireland. AR, RH and SBC were funded by EU-AIMS (European Autism Interventions - A Multicentre Study for Developing New Medications; 115300: FP7/2007-2013), the Templeton World Charitable Foundation, the Simons Foundation Autism Research Initiative (SFARI), the Autism Research Trust and the Innovative Medicines Initiative 2 Joint Undertaking (JU; 777394). The JU receives support from the European Union's Horizon 2020 Research and Innovation Program and EFPIA and AUTISM SPEAKS, Autistica, SFARI. MVL was supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (755816). BA was funded by the European Union's Horizon 2020 research and innovation program under the Marie Sk?odowska-Curie grant agreement (813546), the Baily Thomas Charitable Fund (TRUST/VC/AC/SG/469207686), the Data Driven Innovation Program and the UK Economic and Social Research Council (ES/N018877/1). SBC was funded by the National Institute of Health Research (NIHR) Applied Research Collaboration East of England (ARC EoE) program. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the funders.
Publisher Copyright:
© 2021 The Authors
PY - 2022/2
Y1 - 2022/2
N2 - Prenatal testosterone (pT) is a crucial component in physiological masculinization in humans. In line with the Prenatal Sex Steroid Theory of autism, some studies have found a positive correlation between pT and autistic traits in childhood. However, effects in adolescence have not been explored. Hormonal and environmental changes occurring during puberty may alter the strength or the nature of prenatal effects on autistic traits. The current study examines if pT relates to autistic traits in a non-clinical sample of adolescents and young adults (N = 97, 170 observations; age 13–21 years old). It also explores pT interactions with pubertal stage and timing. PT concentrations were measured from amniotic fluid extracted in the 2nd trimester of gestation via amniocentesis conducted for clinical purposes. Autistic traits were measured by self- and parent-reports on the Autism Spectrum Quotient (AQ) which provides a total score and 5 sub-scores (social skills, communication, imagination, attention switching and attention to detail). Self-reported pubertal stage was regressed on age to provide a measure of relative timing. We found no statistical evidence for a direct association between pT and autistic traits in this adolescent sample (males, females or full sample). Exploratory analyses suggested that pT correlated positively with autistic traits in adolescents with earlier puberty-onset, but statistical robustness of this finding was limited. Further exploratory post-hoc tests suggested the pT-by-pubertal timing interaction was stronger in males relative to females, in self-reported compared to parent-reported AQ and specifically for social traits. These findings require replication in larger samples. Findings have implications for understanding the effects of pT on human behavior, specifically existence of effects in adolescence.
AB - Prenatal testosterone (pT) is a crucial component in physiological masculinization in humans. In line with the Prenatal Sex Steroid Theory of autism, some studies have found a positive correlation between pT and autistic traits in childhood. However, effects in adolescence have not been explored. Hormonal and environmental changes occurring during puberty may alter the strength or the nature of prenatal effects on autistic traits. The current study examines if pT relates to autistic traits in a non-clinical sample of adolescents and young adults (N = 97, 170 observations; age 13–21 years old). It also explores pT interactions with pubertal stage and timing. PT concentrations were measured from amniotic fluid extracted in the 2nd trimester of gestation via amniocentesis conducted for clinical purposes. Autistic traits were measured by self- and parent-reports on the Autism Spectrum Quotient (AQ) which provides a total score and 5 sub-scores (social skills, communication, imagination, attention switching and attention to detail). Self-reported pubertal stage was regressed on age to provide a measure of relative timing. We found no statistical evidence for a direct association between pT and autistic traits in this adolescent sample (males, females or full sample). Exploratory analyses suggested that pT correlated positively with autistic traits in adolescents with earlier puberty-onset, but statistical robustness of this finding was limited. Further exploratory post-hoc tests suggested the pT-by-pubertal timing interaction was stronger in males relative to females, in self-reported compared to parent-reported AQ and specifically for social traits. These findings require replication in larger samples. Findings have implications for understanding the effects of pT on human behavior, specifically existence of effects in adolescence.
KW - amniotic fluid
KW - autism
KW - fetal development
KW - prenatal testosterone
KW - puberty
UR - http://www.scopus.com/inward/record.url?scp=85120756416&partnerID=8YFLogxK
U2 - 10.1016/j.psyneuen.2021.105623
DO - 10.1016/j.psyneuen.2021.105623
M3 - Article
AN - SCOPUS:85120756416
SN - 0306-4530
VL - 136
JO - Psychoneuroendocrinology
JF - Psychoneuroendocrinology
M1 - 105623
ER -